The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K).

Abstract

The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are therapeutic targets for diseases such as cancer, neurodegeneration and immunological disorders as they are key components in regulating cell signalling pathways. In an effort to make probe molecules available for further exploring these targets, we have previously reported PI5P4Kα-selective and PI5P4Kγ-selective ligands. Herein we report the rational design of PI5P4Kα/γ dual inhibitors, using knowledge gained during the development of selective inhibitors for these proteins. ARUK2007145 (39) is disclosed as a potent, cell-active probe molecule with ADMET properties amenable to conducting experiments in cells.

• Authors: Gregory G Aldred, Timothy P C Rooney, Henriette M G Willems, Helen K Boffey, Christopher Green, David Winpenny, John Skidmore, Jonathan H Clarke, Stephen P Andrews
• Journal: RSC medicinal chemistry (RSC Med Chem) Vol. 14 Issue 10 Pg. 2035-2047 (Oct 18 2023) ISSN: 2632-8682 [Electronic] England
• PMID: 37859710 (Publication Type: Journal Article)
• Copyright: This journal is © The Royal Society of Chemistry.